Table 1.
Baseline characteristics and treatment outcomes according to the responder and non-responder groups.
| Total subjects (N = 94) | Responder group (N = 55) | Non-responder group (N = 39) | P value | |
|---|---|---|---|---|
| Age (years) | 61.2 (±10.2) | 58.3 (±10.3) | 65.1 (±8.8) | 0.004* |
| Gender (Male: Female) | 49:45 | 31:24 | 18:21 | 0.379 |
| HbA1C (%) | 7.78 (±1.32) | 7.66 (±1.40) | 7.94 (±1.21) | 0.359 |
| PDR | 32 (34%) | 22 (40%) | 10 (25.6%) | 0.130 |
| Baseline BCVA (LogMAR) | 0.92 (±0.45) | 1.08 (±0.39) | 0.68 (±0.43) | <0.001* |
| Final BCVA (LogMAR) | 0.62 (±0.43) | 0.44 (±0.25) | 0.86 (±0.50) | <0.001* |
| Changes in BCVA (LogMAR) | 0.30 (±0.53) | 0.64 (±0.39) | −0.18 (±0.22) | <0.001* |
| Baseline CST (μm) | 425.2 (±127.4) | 447.2 (±131.5) | 394.1 (±116.0) | 0.032* |
| Final CST (μm) | 328.6 (±99.4) | 310.4 (±86.8) | 354.2 (±110.9) | 0.033* |
| Changes in CST(μm) | −93.4 (±160.3) | −131.3 (±141.6) | −39.9 (±171.5) | 0.009* |
| Number of IVI | 9.24 (±3.55) | 9.51 (±3.68) | 8.87 (±3.37) | 0.421 |
BCVA: best corrected visual acuity, CST: central subfield thickness, HbA1C: glycosylated hemoglobin, LogMAR: logarithm of the minimum angle of resolution, IVI: intravitreal injection, PDR: Proliferative diabetic retinopathy, *P < 0.05.